BRIEF-Seattle Genetics And Beigene Announce Global License Agreement For Advanced Preclinical Product Candidate

Nov 5 (Reuters) - Seattle Genetics, Beigene Ltd:

* SEATTLE GENETICS AND BEIGENE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR ADVANCED PRECLINICAL PRODUCT CANDIDATE

* SEATTLE GENETICS - CO, BEIGENE ENTERED AGREEMENT FOR AN ADVANCED PRECLINICAL PRODUCT CANDIDATE FOR TREATING CANCER

* SEATTLE GENETICS - CO HAS RETAINED RIGHTS TO PRODUCT CANDIDATE IN AMERICAS, EUROPE AND JAPAN

* SEATTLE GENETICS - BEIGENE HAS BEEN GRANTED EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE PRODUCT CANDIDATE IN ASIA AND REST OF WORLD

* SEATTLE GENETICS - CO WILL LEAD GLOBAL DEVELOPMENT, BEIGENE WILL FUND, OPERATIONALIZE PORTION OF CLINICAL TRIALS ATTRIBUTABLE TO ITS TERRITORIES

* SEATTLE GENETICS - CO WILL RECEIVE UPFRONT PAYMENT MILESTONES, FOR A TOTAL DEAL VALUE OF UP TO $160 MILLION AND TIERED ROYALTIES ON ANY PRODUCT SALES Source text for Eikon: Further company coverage: